Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer

EXPERT OPINION ON THERAPEUTIC TARGETS

TAYLOR & FRANCIS LTD

1. NCI NIH HHS [P50 CA090381, P01 CA163227, P50 CA097186] Funding Source: Medline
2. BLRD VA [I01 BX000585, I01 BX003324] Funding Source: Medline
3. VA [5I01BX000585-03, 549385] Funding Source: Federal RePORTER